Amphastar Pharmaceuticals, Inc. (AMPH) SEC filings

AMPHNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3033% below fair value

$28.60−0.46 (-1.58%)

Close on Nov 11, 2026Market cap $1.22BP/E 13.0Yield –

SEC filings

40 of Amphastar Pharmaceuticals's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Quarterly report	10-Q	Sep 30, 2026	Nov 5, 2026	SEC EDGAR
Current report	8-K	Nov 5, 2026	Nov 5, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 6, 2026	SEC EDGAR
Current report	8-K	Aug 6, 2026	Aug 6, 2026	SEC EDGAR
Current report	8-K	Jul 9, 2026	Jul 13, 2026	SEC EDGAR
Current report	8-K	Jul 2, 2026	Jul 8, 2026	SEC EDGAR
Current report	8-K	Jun 1, 2026	Jun 3, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 7, 2026	SEC EDGAR
Current report	8-K	May 7, 2026	May 7, 2026	SEC EDGAR
Proxy statement	DEF 14A	Jun 1, 2026	Apr 13, 2026	SEC EDGAR
Current report	8-K	Mar 12, 2026	Mar 16, 2026	SEC EDGAR
Current report	8-K	Mar 3, 2026	Mar 6, 2026	SEC EDGAR
Current report	8-K	Mar 3, 2026	Mar 6, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Feb 26, 2026	SEC EDGAR
Current report	8-K	Feb 26, 2026	Feb 26, 2026	SEC EDGAR
Current report	8-K	Jan 6, 2026	Jan 12, 2026	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 6, 2025	SEC EDGAR
Current report	8-K	Nov 6, 2025	Nov 6, 2025	SEC EDGAR
Current report	8-K	Oct 21, 2025	Oct 24, 2025	SEC EDGAR
Current report	8-K	Sep 15, 2025	Sep 18, 2025	SEC EDGAR
Current report	8-K	Aug 8, 2025	Aug 12, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 7, 2025	SEC EDGAR
Current report	8-K	Aug 7, 2025	Aug 7, 2025	SEC EDGAR
Current report	8-K	Jul 18, 2025	Jul 21, 2025	SEC EDGAR
Current report	8-K	Jun 2, 2025	Jun 4, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 8, 2025	SEC EDGAR
Current report	8-K	May 7, 2025	May 7, 2025	SEC EDGAR
Proxy statement	DEF 14A	Jun 2, 2025	Apr 14, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Mar 3, 2025	SEC EDGAR
Current report	8-K	Feb 27, 2025	Feb 27, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Nov 7, 2024	SEC EDGAR
Current report	8-K	Nov 6, 2024	Nov 6, 2024	SEC EDGAR
Current report	8-K	Aug 28, 2024	Aug 30, 2024	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2024	Aug 9, 2024	SEC EDGAR
Current report	8-K	Aug 7, 2024	Aug 7, 2024	SEC EDGAR
Current report	8-K	Jun 3, 2024	Jun 4, 2024	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2024	May 10, 2024	SEC EDGAR
Current report	8-K	May 8, 2024	May 8, 2024	SEC EDGAR
Proxy statement	DEF 14A	Jun 3, 2024	Apr 12, 2024	SEC EDGAR
Annual report	10-K	Dec 31, 2023	Feb 29, 2024	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Amphastar Pharmaceuticals's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is AMPH.

Compare: AMPH vs LQDA · AMPH vs ANIP · AMPH vs MNKD · AMPH vs AAPG · AMPH vs EBS

Revenue growth3.1% · median 28.8%

Gross margin46.8% · median 61.1%

Operating margin18.7% · median -9.2%

Net margin13.3% · median -16.6%

Company	Revenue	Growth
ANIP	$1.04B	+25.9%
AMPH	$745.79M	+3.1%
EBS	$649.10M	-17.7%
LQDA	$621.87M	+798.4%
MNKD	$413.37M	+31.7%
AAPG	–	–

Company

Next earnings (est.): Feb 25, 2027, during market hours
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 163
Held by institutions: 66.6%
Auditor: Ernst& YoungLLP
SEC CIK: 1297184

Advertisement
300 × 250

See a number that looks wrong?